About Zymedi
Zymedi is a company based in Incheon (South Korea) founded in 2019.. Zymedi has raised $29.54 million across 2 funding rounds from investors including Industrial Bank of Korea, Company K Partners and UTC Investment. Zymedi offers products and services including ZMA001, ZMP201, ZMC003, and ARS Platform. Zymedi operates in a competitive market with competitors including NGM Biopharmaceuticals, Nimbus Therapeutics, Mirum Pharmaceuticals, Madrigal Pharmaceuticals and Akero Therapeutics, among others.
- Headquarter Incheon, South Korea
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$29.54 M (USD)
in 2 rounds
-
Latest Funding Round
$12.08 M (USD), Series A
May 30, 2023
-
Investors
Industrial Bank of Korea
& 6 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Zymedi
Zymedi offers a comprehensive portfolio of products and services, including ZMA001, ZMP201, ZMC003, and ARS Platform. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Targets pulmonary arterial hypertension for precision medicine applications.
Vaccine candidate for immune-related disorders treatment.
Drug for neurological diseases addressing unmet needs.
Enables development of first-in-class drugs for hard-to-treat conditions.
Funding Insights of Zymedi
Zymedi has successfully raised a total of $29.54M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $12.08 million completed in May 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 2
- Last Round Series A — $12.1M
-
First Round
First Round
(01 Jun 2021)
- Investors Count 7
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May, 2023 | Amount | Series A - Zymedi | Valuation | Company K Partners , UTC Investment |
|
| Jun, 2021 | Amount | Series A - Zymedi | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Zymedi
Zymedi has secured backing from 7 investors, including venture fund and institutional investors. Prominent investors backing the company include Industrial Bank of Korea, Company K Partners and UTC Investment. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital firm investing in tech startups
|
Founded Year | Domain | Location | |
|
Venture capital and private equity investment firm
|
Founded Year | Domain | Location | |
|
Venture capital investments are managed to support startup ecosystems.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Zymedi
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Zymedi
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Zymedi Comparisons
Competitors of Zymedi
Zymedi operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as NGM Biopharmaceuticals, Nimbus Therapeutics, Mirum Pharmaceuticals, Madrigal Pharmaceuticals and Akero Therapeutics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Biologics are developed for cardio-metabolic and liver diseases.
|
|
| domain | founded_year | HQ Location |
Targeted therapeutics for cancer, metabolic, and inflammatory diseases are developed.
|
|
| domain | founded_year | HQ Location |
Small molecule therapeutics are developed for rare diseases treatment.
|
|
| domain | founded_year | HQ Location |
Develops small molecule drugs for the treatment of cardiovascular and metabolic diseases and non-alcoholic steatohepatitis
|
|
| domain | founded_year | HQ Location |
Small molecule therapeutics for metabolic disorders are developed.
|
|
| domain | founded_year | HQ Location |
Antibodies for cancer and infectious disease treatments are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Zymedi
Frequently Asked Questions about Zymedi
When was Zymedi founded?
Zymedi was founded in 2019 and raised its 1st funding round 2 years after it was founded.
Where is Zymedi located?
Zymedi is headquartered in Incheon, South Korea.
Who is the current CEO of Zymedi?
Nam Hoon Kwon is the current CEO of Zymedi.
Is Zymedi a funded company?
Zymedi is a funded company, having raised a total of $29.54M across 2 funding rounds to date. The company's 1st funding round was a Series A of $17.46M, raised on Jun 01, 2021.
What does Zymedi do?
Zymedi was founded in 2019 and is based in Incheon, South Korea. Operations focus on the biotechnology sector, where therapeutics for various diseases are developed. Aminoacyl-tRNA Synthetase-based drugs form the core pipeline, including ZM-A001 targeted at pulmonary arterial hypertension, ZM-C001 for non-alcoholic steatohepatitis, and ZM-C101 for colorectal cancer. Leadership is provided by CEO Nam Hoon Kwon.
Who are the top competitors of Zymedi?
Zymedi's top competitors include Nimbus Therapeutics, NGM Biopharmaceuticals and Madrigal Pharmaceuticals.
What products or services does Zymedi offer?
Zymedi offers ZMA001, ZMP201, ZMC003, and ARS Platform.
Who are Zymedi's investors?
Zymedi has 7 investors. Key investors include Industrial Bank of Korea, Company K Partners, UTC Investment, Korea Venture Investment Corp., and Medytox Venture.